Privacy Statement

Amgen Australia Pty Ltd (Amgen) and Atlantis Health comply with the Privacy Act 1988 (Cth) ("Privacy Act") to ensure that your personal information is protected. In this statement, all references to personal information include sensitive information (such as information about your health).

If you are a healthcare professional, Amgen and Atlantis Health will collect, hold and use your personal information to deliver the Repatha® (evolocumab) and EVENITY® (romosozumab) Co-Pay Program (Program) to your enrolled patients and to continue to improve the Program, including contacting you for follow-up purposes and providing you with materials related to the Program.

If you are a patient, Amgen and Atlantis Health will collect and use your personal information to enrol you in, administer and continue to improve the Program, including providing you with materials and services you request and contacting you for follow-up purposes related to the Program. Amgen and Atlantis Health will collect personal information directly from you where it is reasonable and practicable to do so. Amgen and Atlantis Health may also collect your personal information from your healthcare professional through the enrolment process.

If you provide your email address, telephone and/ or mobile phone number on this form, you also consent to Amgen and Atlantis Health using your email address, telephone and/or mobile phone number to contact you (including by SMS or email) for any of these purposes. Your consent will remain current until you advise us otherwise by writing to us at the relevant address below.

Amgen and Atlantis Health may contract with other persons or organisations to assist in the provision of additional support services for Repatha® (evolocumab) and EVENITY® (romosozumab), or for them to provide feedback to Amgen on how the Program can be improved. Your personal information may be disclosed to such persons or organisations and, in providing a service, they may contact you directly. Amgen requires these persons or organisations to maintain the confidentiality of your personal information and to only use that information for the services they perform. In some instances, they may disclose the personal information they collect from you to other third parties (such as mailhouses) for the purposes of performing services relevant to the Program. If Atlantis Health ceases to be involved in the Program, Atlantis Health may transfer your personal information to Amgen or a third party nominated by Amgen for the purposes of continuing the Program. Amgen will handle all personal information it collects from third parties about you for the purposes and in the manner described in this privacy statement.

If you are a patient and you provide Amgen and Atlantis Health with the details of your healthcare professional, Amgen and Atlantis Health may disclose your personal information to that healthcare professional to confirm that you have enrolled in the Program. Amgen may also use information that it collects as part of the Program in a de-identified form to inform doctors of patient experiences with Repatha® (evolocumab) and EVENITY® (romosozumab), including via publication in medical journals and presentations at clinical meetings.

Amgen continually monitor the safety profile of their products. To support this ongoing process, and to adhere with local and global regulatory obligations, reports of Adverse Events (AE), Other Safety Findings (OSFs) and product quality complaints, in relation to a patient administered an Amgen product, identified as part of your participation in this activity, will be shared with Amgen's Pharmacovigilance department. The information may be disclosed to local and overseas regulatory authorities or other third parties (such as those providing AE case processing activities, or license partners), for the purposes of meeting pharmacovigilance requirements.

Amgen's Pharmacovigilance team may wish to contact you, or your nominated Healthcare Professional (HCP), for further information regarding any adverse events, other safety findings and product quality complaints, identified during your participation in this activity. Your agreement to this is voluntary, and you will be given the option to indicate your consent to this during the provision of the program services.

Amgen and/or Atlantis Health may transfer your personal information overseas. In the event that Amgen and/ or Atlantis Health transfer your personal information outside Australia, Amgen and/or Atlantis Health will comply with the requirements of the Privacy Act that relate to transborder data flows.

Unless you inform us otherwise, by submitting this form, you consent to Amgen and Atlantis Health collecting, using and disclosing your personal information in this way. If you do not provide the information to us, we will be unable to enrol you in the Program.

You are able to withdraw from the Program at any time by advising us in writing by emailing Repatha® (evolocumab) and EVENITY® (romosozumab) @amgencostshare.com.au.

You can find a copy of Atlantis Health's privacy policy at https://www.atlantishealth.com/privacy-notice. Please address all privacy complaints and requests to update or access information to privacy@atlantishealth.com.

For more information on Amgen's collection, use and disclosure of personal information, refer to our Privacy Statement at www.amgen.com.au and Amgen's Data Privacy Statement below.

Amgen may collect and process personal information about you in order to administrate and/ or manage the Program. Personal information will include non-sensitive information such as your name and contact information (e.g. phone number and email), as well as sensitive information (e.g. medical history). Amgen will only process your personal information for the purposes mentioned above. Amgen processes your personal data for the duration of the contractual relationship between you and Amgen or for as long as required by applicable laws (e.g. tax laws).

This information may be transferred to a third party for providing services under this Agreement (event organiser, travel agencies) processing and/or processed and securely stored in countries outside of that in which it was collected, such as the United States or other non-EU/EEA countries. Transfers of personal information in countries not deemed adequate are done using appropriate safeguards such as Standard Contractual Clauses. To obtain a copy of these safeguards, please contact your Data Protection Officer at privacy@amgen.com.

Amgen has a legal obligation to report adverse drug events ('side effects') to various local and international health authorities (e.g., the U.S. Federal Food and Drug Administration, the European Medicines Agency, the Australian Therapeutic Goods Administration and the New Zealand Medicines and Medical Devices Safety Authority) and to monitor product complaints. Personal information provided to the Program may be (i) monitored by Amgen or its service providers for safety related data and product complaints in order to ensure compliance with these legal reporting requirements, and (ii) reported to local or international health authorities. Amgen may contact you or your physician for additional information to fulfil its reporting obligations. Your personal information may be combined with the information of others who participate in the Program in order to generate aggregated data that does not contain identifying information ("Aggregated Data"). Aggregated Data may be used by Amgen and its service providers to improve and/or refine the Program, to design and implement other patient programs and for research purposes including the identification of trends such as product utilisation, adherence or outcomes.

For these purposes, Atlantis Health may, on a confidential basis, collect your personal information and disclose it to your healthcare providers, insurers and/or other payers, Amgen and/or Amgen's agents and service providers (e.g., information technology providers). If, from time to time, another service provider is appointed by Amgen to administer the Program, your personal information will be transferred to this service provider to ensure the continuity of the Program services to you.

Amgen is a multi-national company headquartered in the United States. Amgen maintains data centres around the world, including in the European Union and the United States. Amgen may process personal information in global databases that can be accessed by authorised Amgen personnel worldwide. Transfers of personal information among Amgen and its group entities follow applicable laws and our Binding Corporate Rules (BCRs). For more information on the BCRs, including your ability to file a complaint about any processing of your personal information in violation of the BCRs, please visit http://www.amgen.com/bcr/.

Regardless of the country where your personal information is either collected or processed, Amgen maintains appropriate administrative, technical and physical safeguards to protect information about you. You may access, correct or request deletion of your personal information, as well as request your right to data portability, subject to certain restrictions imposed by law, by contacting your Data Protection Officer by email at privacy@amgen.com. You may also lodge a complaint either by contacting your Data Protection Officer or directly to your Data Protection Authority.

AUS-NP-0725-80005
Date of preparation: August 2025